arrow_back Back to App

Increased Cancer Research Funding and Study on Drug Shortages.

This law significantly boosts funding for the National Cancer Institute (NCI) from 2026 to 2030 to accelerate the search for more effective cancer treatments and cures. It also mandates a detailed study into the causes of critical oncology drug shortages, aiming to improve medication availability for patients. Citizens can expect potentially faster breakthroughs in oncological medicine.
Key points
Substantial additional funding allocated to the National Cancer Institute (NCI) for cancer research over five years (2026-2030), potentially leading to faster medical breakthroughs.
Requirement for a study on the reasons behind cancer drug shortages, including supply chain issues and approval delays, to ensure patients have consistent access to necessary treatments.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3873
Sponsor: Rep. Fitzpatrick, Brian K. [R-PA-1]
Process start date: 2025-06-10
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

KO Cancer Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3873.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-10.

What are the main provisions?

Key points include:

  • Substantial additional funding allocated to the National Cancer Institute (NCI) for cancer research over five years (2026-2030), potentially leading to faster medical breakthroughs.
  • Requirement for a study on the reasons behind cancer drug shortages, including supply chain issues and approval delays, to ensure patients have consistent access to necessary treatments.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Fitzpatrick, Brian K. [R-PA-1].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health